Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Jasper Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cost of revenue
34.3
41.6
Research and development
15.9
25.4
34.6
51.8
55.8
63.1
General and administrative
4.8
11.4
16.6
17.1
20.4
20.8
Operating expenses
20.7
36.8
51.2
68.9
76.2
83.9
Operating income
-20.7
-36.8
-51.2
-68.9
-76.2
-83.9
Interest income
0.24
0.7
5.2
5.06
1.74
Other non-operating income
-0.08
0.59
4.4
4.97
8.08
Pre-tax income
-6.44
Income tax
0.04
0
0
Net income
-31.7
-30.6
-37.7
-64.5
-71.3
-75.8
EBITDA
-36.5
-50.2
-67.8
-74.9
-82.8
EPS, basic
-51.85
-26.98
-10.33
-6.18
-4.89
-3.95
EPS, diluted
-51.85
-26.98
-10.33
-6.18
-4.89
-3.95
Shares, basic (weighted)
0.61
1.14
3.65
10.4
14.6
19.2
Shares, diluted (weighted)
0.61
1.14
3.65
10.4
14.6
19.2
Balance sheet
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
19.8
84.7
38.3
86.9
71.6
28.7
Other current assets
0.25
0.22
0.12
0.3
0.65
0.66
Total current assets
20.7
87.8
41.7
88.9
75.8
34.6
Property, plant and equipment
0.69
3.69
3.57
2.73
1.88
0.1
Lease right-of-use assets
1.34
1.15
1.89
1.47
0.98
0.5
Long-term investments
100
Other non-current assets
0.3
0.65
0.76
1.34
0.82
0.11
Total assets
23.4
93.7
48.4
94.9
79.9
35.8
Accounts payable
1.42
3.92
1.77
4.15
4.03
6.22
Accrued liabilities
0.93
1.15
1.59
1.77
3.1
1.59
Total current liabilities
4.01
8.02
7.07
12.4
15.2
13.2
Lease liabilities
1.62
2.38
2.79
1.81
0.72
Other non-current liabilities
0.85
0.64
2.35
2.26
2.26
2.26
Total liabilities
14.6
24.1
12.4
16.5
18.2
31.6
Paid-in capital
1.68
137
141
248
303
321
Retained earnings
-36.8
-67.5
-105
-170
-241
-317
Shareholders' equity
-35.1
69.5
36
78.4
61.7
4.15
Total equity
-35.1
69.5
36
78.4
61.7
4.15
Total liabilities and equity
23.4
93.7
48.4
94.9
79.9
35.8
Shares outstanding
0.28
3.77
3.8
11.2
15
28
Cash flow statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-31.7
30.6
37.7
-64.5
-71.3
-75.8
Depreciation and amortization
0.38
0.98
1.11
1.37
1.06
Stock-based compensation
1.21
1.05
4.09
5.21
6.62
6.71
Change in receivables
0.6
Change in payables
0.36
2.94
-2.15
2.38
-0.12
2.19
Cash from operations
-18.3
-33.7
-45.9
-52.1
-62.6
-77.2
Cash from investing
0.2
-2.43
-0.58
-0.27
-0.53
0.01
Stock issued
0.05
0.24
0.03
101
47.2
6.45
Cash from financing
11.3
101
0.06
101
47.9
34.2
Net change in cash
-0.44
64.9
-46.4
48.6
-15.3
-42.9
Income taxes paid
0.06
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.61 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-2,248.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-269.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-93.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-51.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-55.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-9.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
8.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
31.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
73.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
99.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.47x
Current assets / current liabilities.
Quick ratio
0.93x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.93x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$2.10
Cash from operations / diluted weighted shares.
Book value per share
$0.05
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
14.3x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
14.3x
Market cap / tangible book value, when positive.
Earnings yield
-156.8%
Net income / market cap (the inverse of P/E).
Was Jasper Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $75.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.